ena-STUDY-MDC BERLIN-16-04-2020-11:44:05:902-393
Modulation of EBAG9 expression in CAR T cells
T cells engineered to express chimeric antigen receptors (CARs) have revolutionized treatment of B-cell malignancies. However, improving the efficacy of engineered T cells without compromising their safety is warranted. Here, we compared the transcriptional profile of human BCMA and EBAG9-modulated BCMA CAR T cells as the estrogen receptor-binding fragment-associated antigen 9 (EBAG9) inhibits the cytolytic capacity of CTLs. CAR T cells were generated from PBMCs of healthy volountary donors by retroviral transduction and were cultured for 10 days before CAR-expressing cells were sorted and RNA was extracted. Transcriptome analysis did not reveal additional risks regarding genotoxicity or differentiation due to EBAG9-modulation.
T cells engineered to express chimeric antigen receptors (CARs) have revolutionized treatment of B-cell malignancies. However, improving the efficacy of engineered T cells without compromising their safety is warranted. Here, we compared the transcriptional profile of human BCMA and EBAG9-modulated BCMA CAR T cells as the estrogen receptor-binding fragment-associated antigen 9 (EBAG9) inhibits the cytolytic capacity of CTLs. CAR T cells were generated from PBMCs of healthy volountary donors by retroviral transduction and were cultured for 10 days before CAR-expressing cells were sorted and RNA was extracted. Transcriptome analysis did not reveal additional risks regarding genotoxicity or differentiation due to EBAG9-modulation.